Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,638 SEK | -0.30% | -2.27% | +20.95% |
12:01pm | ASTRAZENECA : Gets a Buy rating from JP Morgan | ZD |
11:25am | European Midday Briefing : Stocks, Commodities Gain on Fresh China Policy Support | DJ |
Sales 2024 * | 51.56B 551B 4,292B | Sales 2025 * | 55.37B 592B 4,608B | Capitalization | 239B 2,548B 19,853B |
---|---|---|---|---|---|
Net income 2024 * | 8.62B 92.15B 718B | Net income 2025 * | 10.3B 110B 857B | EV / Sales 2024 * | 5.03 x |
Net Debt 2024 * | 20.65B 221B 1,719B | Net Debt 2025 * | 14.01B 150B 1,166B | EV / Sales 2025 * | 4.56 x |
P/E ratio 2024 * |
28
x | P/E ratio 2025 * |
23.4
x | Employees | 89,900 |
Yield 2024 * |
2% | Yield 2025 * |
2.11% | Free-Float | 96.62% |
Latest transcript on AstraZeneca PLC
1 day | -0.32% | ||
1 week | -2.27% | ||
Current month | -2.06% | ||
1 month | +7.03% | ||
3 months | +21.26% | ||
6 months | +23.04% | ||
Current year | +20.95% |
Managers | Title | Age | Since |
---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 01/12/01 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 01/21/01 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/20/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 01/17/01 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 01/13/01 |
Philip Broadley
BRD | Director/Board Member | 63 | 27/17/27 |
Date | Price | Change | Volume |
---|---|---|---|
20/24/20 | 1,637 | -0.40% | 57 409 |
17/24/17 | 1,644 | -0.06% | 143,523 |
16/24/16 | 1,644 | -0.27% | 224,814 |
15/24/15 | 1,649 | -1.20% | 178,458 |
14/24/14 | 1,669 | -0.36% | 196,703 |
Delayed Quote Nasdaq Stockholm, May 20, 2024 at 04:00 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B | |
-0.52% | 162B |
- Stock Market
- Equities
- AZN Stock
- AZN Stock